

Index

A

- ABC1*, 188
- ABPA. *See* Allergic bronchopulmonary aspergillosis
- Acanthamoeba castellanii*, 10
- Ace2*, 69
- Acrophialophora*, 520
- Acrophialophora fusispora*, 520
- AD. *See* Atopic dermatitis
- AD-HIES. *See* Autosomal dominant hyper-immunoglobulin E syndrome
- Adenylate kinase, lysis assay for drug development, 277
- ADH5*, 172
- Adh5*, 371
- AFR1*, 370
- Afr1*, 367
- AIDS. *See* HIV/AIDS
- AIF1*, 84
- Allergic bronchopulmonary aspergillosis (ABPA), 439
- Als3*, 168–169, 202, 220–223, 245, 293, 417–418
- ALS proteins, 164–165
- Alternaria*, 14, 521–522
- Alternaria alternata*, 124, 519, 521–522
- Alternaria chlamydospora*, 521–522
- Alternaria dianthicola*, 521
- Alternaria infectoria*, 521–522
- Alternaria longpipes*, 521
- Alternaria tennissima*, 521
- Amphotericin B
 - adverse effects, 328
 - biofilms in resistance, 173–174
 - candidiasis management, 339–340, 352
 - Cryptococcus* treatment, 342–345, 350–351
 - endemic fungi infection management, 357
 - entomophthoramycosis management, 506–507
 - invasive aspergillosis management, 355
 - mechanism of action, 272
 - mucormycosis management, 487–488
 - pharmacodynamics of lipid formulations, 307–308
 - structure, 273
- AN2690, 279–280
- Aneuploidy. *See also* Ploidy change
 - consequences, 83–85
 - loss of heterozygosity, 84–85
 - mechanisms in generation, 81–83
 - overview, 80–81
- Anhidrotic ectodermal dysplasia with immunodeficiency (EDA-IE), 153
- Anidulafungin
 - candidiasis management, 340
 - structure, 273
- Antibody directed cell toxicity, 108
- Antibody therapy. *See* Immunotherapy
- Antifungals. *See* Drug development; *specific drugs*
- APECED, 105, 150–151
- App1*, 185
- APR1*, 239
- ARG4*, 68–69
- Armillaria mellea*, 26
- Ascomycetes, 196
- Ascomycota, 4–8, 11–14, 23–25, 33, 120
- Ashbya gossypii*, 196
- Aspergillosis. *See* Allergic bronchopulmonary aspergillosis; Invasive aspergillosis
- Aspergillus*
 - evolution, 24, 27, 31
 - overview, 12–14
- Aspergillus flavus*, 52, 435–436
- Aspergillus fumigatus*
 - amino acid metabolism, 240
 - aspergillosis. *See* Invasive aspergillosis
 - B-cell immunity, 107–108
 - biofilm, 162, 170, 173–174
 - carbon assimilation, 240, 243
 - cell invasion
 - adherence mechanisms, 224–225
 - molecular mechanisms, 224
 - overview, 223–224
 - clinical trials
 - overview, 354–355
 - prospects, 355
 - dendritic cell
 - immunotherapy, 290
 - response, 94, 97
 - diagnosis, 265
 - drug resistance, 368
 - ecology, 433
 - evolution, 24, 26–29, 32
 - innate immunity, 121–122, 124, 126–127
 - iron metabolism, 246
 - laboratory identification and biology, 433–436
 - macrophage engulfment, survival, and replication, 184–185
 - overview, 12–13
 - pattern recognition receptors, 100

Index

- Aspergillus fumigatus* (Continued)
ploidy change, 75–77
section *Fumigati*, 432–433
sexual reproduction
 drug resistance role, 53
 other *Aspergillus* species, 521
 overview, 51
 pathogen population biology significance,
 52–53
 sexual cycle, 51–52
T-cell immunity, 107
vaccination, 291
zinc assimilation, 247
- Aspergillus lentulus*, 52–53
- Aspergillus nidulans*
aspergillosis. *See* Invasive aspergillosis
chronic granulomatous disease, 146
laboratory identification and biology, 433–436
morphogenesis, 195, 198
ploidy change, 76–78
- Aspergillus niger*, 52, 434–436
- Aspergillus oryzae*, 197
- Aspergillus terreus*, 52, 434–435
- Aspf2, 247
- Ato5, 238
- Atopic dermatitis (AD), *Malassezia* role, 475–476
- Atx1, 397
- Aureobasidium*, 522
- Autosomal dominant hyper-immunoglobulin
 E syndrome (AD-HIES), 148–149
- Autosomal recessive hyper-immunoglobulin
 E syndrome, 153
- Axl2, 198
- B**
- Backusella circina*, 494
- Bad1, 228
- Basidiobolus*
 clinical features, 502–503
 diagnosis, 505–506
 ecology, 496–497
 epidemiology, 496–497
 evolution, 25
 life cycle, 499
 management, 506–507
 overview, 5–4, 494–495
 pathogenesis, 502
 taxonomy, 495–498
- Basidiobolus heterosporus*, 497
- Basidiobolus lacerate*, 497
- Basidiobolus meristosporus*, 497
- Basidiobolus microspores*, 497
- Basidiobolus ranarum*, 4, 496–497, 488.503, 506–507
- Basidiomycetes, 196–197
- Basidiomycota, 8–11, 25–26, 120
- Basidiomycota, 14
- Batrachochytrichium*, 25
- B cell, pathogen response, 107–108
- BCR1*, 165, 168
- Bcr1, 167, 169, 420
- Bcy1, 203
- Bgl2, 172
- Biatriospora*, 522
- Biatriospora mackinonii*, 522
- Bin1, 207
- Biofilm
 comparative genomics, 168–169
 drug resistance
 azoles, 371
 echinocandins, 374
 extracellular matrix
 Candida
 drug resistance role, 170–171
 eDNA in drug resistance, 173
 glucan production, 171–172
 production, 169–170
 Aspergillus drug resistance, 173–174
 genetic control of development, 162, 164–168
 multispecies biofilms, 168
 prospects for study, 174
 rationale for study, 161–162
 species and clinical significance, 163–164
- Bipolaris*, 14, 522
- Bipolaris australiensis*, 522
- Bipolaris hawaiiensis*, 519, 522
- Bipolaris spicifera*, 522
- Black fungi
 Acrophialophora, 520
 Alternaria, 520–522
 antifungal therapy, 530–531
 Aureobasidium, 522
 Biatriospora, 522
 Bipolaris, 522
 Chaetomium, 523
 Chladophialophora, 523
 clinical spectrum of diseases, 518–521
 Curvularia, 523
 Cyphellophora, 523–524
 diagnosis, 529–530
 Exophiala, 524–525
 Exserohilum, 525
 Falciformispora, 525
 Fonsecaea, 525–526
 Hortaea, 526
 Knufia, 526
 Madurella, 526
 Medicopsis, 526
 Neoscytalidium, 526–527
 Ochoconis, 527
 overview, 517–518
 Phaeoacremonium, 527

- Phialophora*, 527
- Phoma*, 527–528
- Pseudochaetosphaeronea*, 528
- Pyrenochaeta*, 528
- Rhinochadiella*, 528
- Trematosphaeria*, 528–529
- Veronaea*, 529
- Verruconis*, 529
- Blastomyces*, 4–5, 24, 27
- Blastomyces dermatitidis*
 - cell invasion, 228
 - diagnosis, 266
 - epidemiology, 452
 - evolution, 26
 - morphogenesis, 201, 205
 - T-cell immunity, 102, 107
 - thermal dimorphism, 452–453
 - vaccination, 292
- Bni1, 199
- Brg1, 204
- Bud1, 198
- Bud3, 198
- Bud4, 198
- Bud8, 198
- Bud9, 198

- C**
- CalA, 224
- CAN1, 239
- CAN2, 399
- Candida*
 - evolution, 24, 28, 30–31
 - overview, 11–12
 - pathogens, 413–414
 - taxonomy, 413–416
 - treatment principles. *See Candida treatment principles*
 - vaginosis mycobiome, 560
- Candida albicans*
 - aneuploidy, 80, 82, 85
 - B-cell immunity, 107–108
 - biofilm
 - comparative genomics, 168–169
 - drug development, 276
 - extracellular matrix
 - drug resistance role, 170–171
 - eDNA in drug resistance, 173
 - glucan production, 171–172
 - production, 169–170
 - genetic control of development, 162, 164–168
 - multispecies biofilms, 168
 - carbon assimilation, 240–244
 - cell invasion
 - endothelial cell, 122–123
 - epithelial cell, 119–122
 - drug resistance, 367–368, 370–371
 - epidemiology, 413–414
 - evolution, 26–28, 30–33
 - genome profiling
 - gene-deletion methods, 68–69
 - homozygous knockouts, 69
 - industry collections, 69–70
 - resources, 65
 - transcription factor knockouts, 69
 - genome studies, 416–419
 - innate immunity, 121–122, 124–126, 129
 - iron metabolism, 245–246
 - life cycle and genome, 67–68
 - macrophage engulfment, survival, and replication, 180–184
 - morphogenesis, 200–209
 - nitrogen assimilation, 237–240
 - overview, 11–12
 - parasexual reproduction, 47–51
 - pattern recognition receptors, 100–102
 - ploidy change, 74–75, 77–79
 - vaccination, 291, 294
 - zinc assimilation, 247
- Candida dubliniensis*
 - evolution, 26, 31
 - genome studies, 418–419
- Candida glabrata*
 - carbon assimilation, 240
 - drug resistance, 370–371
 - epidemiology, 413–414
 - evolution, 33
 - genome studies, 420–422
 - iron metabolism, 245–246
 - macrophage engulfment, survival, and replication, 180–184
 - nitrogen assimilation, 237, 239
 - overview, 11
 - zinc assimilation, 247
- Candida guilliermondii*, 420
- Candida krusei*
 - epidemiology, 413–414
 - overview, 11
- Candida lusitanae*, 1, 420, 77, 82
- Candida metapsilosis*, 28
- Candida orthopsilosis*, 28
- Candida parapsilosis*
 - biofilms 166, 168–169
 - cell invasion, 223
 - epidemiology, 413–414
 - evolution 28
 - genome studies, 419–420
 - nitrogen assimilation, 237
 - overview 11
- Candida treatment principles*
 - antifungal agents and spectrum of activity, 340
 - clearance confirmation, 339

Index

- Candida* treatment principles (*Continued*)
- clinical trials
 - overview, 352–353
 - prospects, 353
 - disseminated infection
 - bone, 341
 - central nervous system, 341
 - endocardium, 341
 - eye, 339
 - renal tract, 339, 341
 - drug resistance. *See* Drug resistance
 - general treatment principles. *See* Treatment principles, mold infection
 - meningoencephalitis in HIV, 339
 - overview, 337–338
 - rapid and effective antifungal therapy, 338
 - source removal, 338
 - therapy modification according to species
 - determination and susceptibility testing, 338
- Candida tropicalis*
- epidemiology, 413–414
 - evolution, 28
 - genome studies, 77, 419–420
 - overview, 11
- Cap1p, 183
- Carbon assimilation
- central carbon metabolism
 - regulation in host niches, 242–243
 - regulatory rewiring, 241–242
 - overview, 240–241
 - virulence factor impact, 243–244
- CARD9, signaling defects and fungal infection
- susceptibility, 152–153
- Caspase-1, 129
- Casposungin
- candidiasis management, 340
 - mechanism of action, 274
 - structure, 273
- CatB, 188
- CatP, 188
- Cbp1, 202, 455
- Ccc1, 247
- Ccc2, 397
- Cch1, 206
- CD11b, 224
- CD18, 224
- CD44, 226–227
- Cdc3, 200
- Cdc10, 200
- Cdc11, 200
- Cdc12, 200
- Cdc35, 208
- Cdc42, 194–195, 198–200, 206
- Cdk1, 206
- CDR1, 367–369, 372–373
- CDR2, 367–368, 370
- CDR3, 367
- CDR4, 367
- CDR11, 367
- CFEM proteins, 164, 169, 173
- Cfl1, 209, 225
- CfmA, 224
- CfmC, 224
- Cfo1, 246, 399
- Cft1, 246
- CGD. *See* Chronic granulomatous disease
- Chaetomium*, 523
- Chaetomium atrobrunneum*, 523
- Chaetomium funicola*, 523
- Chaetomium globusum*, 523
- Chaetomium perlucidum*, 523
- Chaetomium strumarium*, 523
- Chitin synthase, drug resistance, 374–376
- Chladophialophora*, 523
- Chladophialophora arxii*, 523
- Chladophialophora bantiana*, 523
- Chladophialophora boppii*, 523
- Chladophialophora carrionni*, 523
- Chladophialophora devriesii*, 523
- Chladophialophora emmonsii*, 523
- Chladophialophora saturnica*, 523
- Chromoblastomycosis, 518
- Chronic granulomatous disease (CGD),
fungal infection susceptibility, 141,
146, 439
- Chs2, 375
- Chs8, 375
- Cir1, 247, 399
- Cla4, 199
- Cladophialphora bantianum*, 14
- Clinical trials. *See* Drug development
- Cln1, 207
- Clostridium difficile* diarrhea, mycobiome,
558–560
- CLR. *See* C-type lectin
- CMV. *See* Cytomegalovirus
- CNA1, 397
- Cnc1560, 197
- CnPIb1, 186
- Coccidioides*, 4–5, 7, 24, 27, 31–32
- Coccidioides immitis*
- evolution, 23, 26–29, 31–32
 - host defense, 487
 - innate immunity, 127
 - macrophage engulfment, survival, and replication,
186–187
 - morphogenesis, 201
 - overview, 4
 - T-cell immunity, 102
 - thermal dimorphism, 453–454
 - vaccination, 291

- Coccidioides posadasii*
 - evolution, 27, 31–32
 - macrophage engulfment, survival, and replication, 186–187
 - overview, 4
 - thermal dimorphism, 453–454
 - vaccination, 291
- Comparative genomics, fungus evolution, 30–32
- Complement fixation, diagnostics, 259
- Complement receptor 3 (CR3), 128
- Conidiobolus*
 - clinical features, 502–505
 - diagnosis, 505–506
 - ecology, 496–497
 - epidemiology, 496–497
 - life cycle, 499–501
 - management, 506–507
 - overview, 3–4, 494–495
 - pathogenesis, 502
 - taxonomy, 495–496, 498, 500–501
- Conidiobolus brefeldianus*, 496
- Conidiobolus coronatus*, 4, 496, 500–501, 503–504, 507
- Conidiobolus firmipelleus*, 496
- Conidiobolus incongruus*, 4, 496, 501, 505
- Conidiobolus lampragues*, 496, 500, 504–505
- Conidiobolus minor*, 498
- Conidiobolus osmodes*, 496
- Conidiobolus pumilus*, 496
- Conidiobolus rhyosporus*, 496
- Conidiobolus thromboides*, 496
- Conidiobolus utriculosis*, 498
- Contact sensing, hyphal morphogenesis, 206
- Copper, transport, 247
- CotH2, 228
- CotH3, 228
- CpcA, 240, 248
- CPS1, 227
- CR3. *See* Complement receptor 3
- CRAG test, 344
- CrAg LFA, diagnostics, 265–267
- Cryptococcus*
 - evolution, 24–25, 30
 - overview, 8–11
 - treatment principles. *See* *Cryptococcus* treatment principles
- Cryptococcus gattii*
 - aneuploidy, 81
 - Cryptococcus neoformans* comparison
 - genotype, 393–394
 - phenotype, 393
 - diagnosis, 266
 - ecology, 387–388
 - environmental sensing and response, 399–400
 - epidemiology of infection, 389
 - history of study, 386
 - immune response and pathogenesis, 389–390
 - life cycle, 391–392
 - macrophage engulfment, survival, and replication, 185–186
 - morphogenesis, 196–197, 205, 208
 - overview, 8–10
 - ploidy change, 74–76, 79–80
 - sexual reproduction, α - α opposite sex bisexual reproduction
 - genetic hybrid studies, 44
 - monokaryotic fruiting, 43
 - overview, 42
 - population genetics studies, 45–47
 - unisexual reproduction, 43–44
 - virulence links, 47
 - stress response and signaling, 400–402
- Cryptococcus neoformans*
 - aneuploidy, 81, 83–84, 86
 - antibody therapy, 287–289
 - B-cell immunity, 107–108
 - biofilm, 174
 - carbon assimilation, 242–243
 - cell invasion, 225–227
 - Cryptococcus gattii* comparison
 - genotype, 393–394
 - phenotype, 393
 - diagnosis, 264–265
 - drug resistance, 367, 391
 - ecology, 387–388
 - environmental sensing and response, 399–400
 - epidemiology of infection, 388–389
 - evolution, 25, 27–29, 32–33
 - genome profiling
 - capsule-independent phagocytosis inhibition, 66
 - cross-species genetic interaction mapping, 67
 - gene-deletion methods, 65–66
 - resources, 65
 - SREBP pathway in virulence, 66–67
 - systematic genetic analysis of virulence, 66
 - history of study, 385–386
 - host defense, 487
 - immune response and pathogenesis, 389–390
 - innate immunity, 121–122
 - iron metabolism, 246–247
 - life cycle, 64, 391–392
 - macrophage engulfment, survival, and replication, 182, 185–186
 - morphogenesis, 196–197, 205, 208
 - overview, 8–10
 - ploidy change, 74–76, 79–80
 - sexual reproduction, α - α opposite sex bisexual reproduction
 - genetic hybrid studies, 44
 - monokaryotic fruiting, 43
 - overview, 42
 - population genetics studies, 45–47
 - unisexual reproduction, 43–44
 - virulence links, 47
 - stress response and signaling, 400–402

Index

Cryptococcus neoformans (Continued)

- T-cell immunity, 104–105, 128
- taxonomy and nomenclature, 386–387
- vaccination, 292
- virulence factors
 - capsule
 - melanization, 397
 - regulation of formation and secretion, 396–397
 - structure and synthesis, 394–395
 - degradation enzymes, 398–399
 - growth at body temperature, 397–398
- Cryptococcus neoformans* var. *grubii*, 9–10, 28, 394
- Cryptococcus* treatment principles
 - clinical trials
 - overview, 350–351
 - prospects, 351–352
 - complications contributing to persistent or relapsed infection, 344–345
 - CRAG screening and preemptive treatment, 344
 - drug resistance. *See* Drug resistance
 - general treatment principles. *See* Treatment principles, mold infection
 - immunity restoration and inflammation management, 343–344
 - intracranial pressure elevation management, 343
 - meningoencephalitis in HIV, 342–343
 - overview, 341–342
 - rapid and effective antifungal therapy, 342–343
 - risk stratification, 342
 - toxicity minimization, 343
- C-type lectin (CLR), overview, 98–100
- CSH1*, 172, 371
- CSMA*, 376
- CSMB*, 376
- CSP1*, 419
- CSP2*, 419
- CspA*, 224
- Csy1*, 239
- Cta1p*, 183
- Ctr1*, 247
- Curvularia*, 14, 523
- Curvularia aerea*, 523
- Curvularia brachyspora*, 523
- Curvularia clavata*, 523
- Curvularia geniculata*, 523
- Curvularia inaequalis*, 523
- Curvularia lunata*, 519, 523
- Curvularia pallescens*, 523
- Curvularia verruculosa*, 523
- Cyclosporine A, 489
- CYP51A. *See* Erg11
- Cyphellophora*, 523–524
- Cyphellophora pluriseptata*, 520
- Cyr1*, 202–203, 205–206, 208
- Cytomegalovirus (CMV), 330

D

- Dandruff, *Malassezia* role, 475
- DC. *See* Dendritic cell
- DC-SIGN, innate immunity, 128
- Dectin-1
 - CARD9 signaling defects and fungal infection susceptibility, 152–153
 - gut inflammation role, 559–560
 - pathogen recognition, 100, 105, 126–127, 179–180, 290
- Dectin-2, pathogen recognition, 100–101, 127
- Dectin-3, pathogen recognition, 101
- Deferasirox, mucormycosis management, 488
- Deferoxamine, mucormycosis risks, 485
- Dendritic cell (DC)
 - conventional dendritic cells, 94, 96
 - functional overview, 94–95, 122
 - immunotherapy, 289–290
 - intestine, 97
 - lung, 97
 - migratory dendritic cells, 96
 - monocyte-derived dendritic cells, 97–98
 - plasmacytoid dendritic cells, 94
 - skin, 96
 - vaccination, 290
- Dermatophytes
 - genera, 467
 - genome features and analysis, 469, 472–474
 - mycobiome analysis of skin, 469–470
 - overview, 470
 - phylogenetic relationships, 468
 - skin diseases
 - overview, 467–469
 - species and epidemiology, 471–472
 - treatment, 472
- Diabetes, mucormycosis risks, 485
- Diagnosis, fungal infection
 - antigen detection
 - advantage and limitations, 266
 - cryptococcosis, 264–265
 - galactomannan, 265–266
 - pan-fungal detection of β -glucan, 266
 - black fungi, 529–530
 - entomophthoromycosis, 505–506
 - molecular diagnostics
 - challenges, 263–264
 - culture-based methods, 260–262
 - non-culture-based methods, 258–260
 - proteomics, 262–263
 - overview, 257–258
 - prospects, 255–267
 - sample collection, 258
 - serology, 258–259
- Dimorphism. *See* Thermally dimorphic fungi
- DLH1*, 79

- DOCK8, deficiency and fungal infection susceptibility, 153
- Drug development. *See also specific drugs*
challenges, 275
clinical needs, 274–275
clinical trials
 candidiasis
 overview, 352–353
 prospects, 353
 cryptococcosis
 overview, 350–351
 prospects, 351–352
 endemic fungi infection, 356–358
 invasive aspergillosis
 overview, 354–355
 prospects, 355
 historical perspective, 274
 infection classification, 272
 overview of current therapies, 272–274
 pharmacodynamics. *See* Pharmacodynamics, antifungals
 pharmacokinetics. *See* Pharmacokinetics, antifungals
 process and new approaches, 275–278
 prospects, 281
 targets and molecular scaffolds, 278–280
- Drug resistance. *See also specific drugs and organisms*
Aspergillus sexual reproduction role, 53
biofilm extracellular matrix
 Aspergillus drug resistance, 173–174
 Candida
 drug resistance role, 170–171
 eDNA in drug resistance, 173
- mechanisms
 assessment, 364–365
 azoles
 biofilms, 371
 chromosomal abnormalities, 370
 efflux, 367–368
 Erg11 substitutions and alterations, 364, 366–367
 Hsp90, 372
 MDR expression regulation, 368–370
 messenger RNA stability, 372–373
 mitochondrial defects, 370–372
 multiple mechanisms, 371
 uptake, 367
 echinocandins
 adaptive cellular factors, 374
 biofilms, 374
 cell integrity circuit, 376–377
 chitin synthase, 374–376
 FKS substitutions and polymorphisms, 373–374
 Hsp90, 376
 prospects for study, 377
- DTRK3, 226
Dur31, 238, 367
Dutch elm disease, 201
- E**
- E1210, 279
Eap1, 168
EC. *See* Epithelial cell
Echinocandin, structure, 273
EDA-IE. *See* Anhidrotic ectodermal dysplasia with immunodeficiency
eDNA, biofilms and eDNA in drug resistance, 173
Eed1, 207
EFG1, 420–421
Efg1, 169, 203, 207–208, 244, 420
Ena1, 402
Endothelial cell, *Candida* invasion, 122–123
ENO1, 242
Entomophthoromycota. *See also Basidiobolus; Conidiobolus*
 ecology, 496–497
 epidemiology, 496–497
 life cycle, 499
 overview, 3–4, 494–495
 taxonomy, 495–498, 500
- Enumafungin, 279
Enzyme immunoassay, diagnostics, 259
EPA genes, 420–421
Epidermophyton, 8
Epithelial cell (EC)
 Candida invasion, 119–122
 innate immunity, 123
- ERG11, 83, 85
ERG25, 400
Erg3, 367, 372
Erg11, 277, 280, 364, 366–367, 370–371, 377, 391, 492
Exophiala, 24, 524–525
Exophiala dermatitidis, 14, 525
Exophiala oligosperma, 525
Exophiala spinifera, 525
Exophiala xenobiotica, 525
Exserohilum, 525
Exserohilum longirostratum, 525
Exserohilum mcginisii, 525
Exserohilum rostratum, 525
- F**
- Falciformispora, 525
Falciformispora senegalensis, 525
Falciformispora tompkinsii, 525
Fbp1, 241
FCA1, 367
FCY2, 367
FCY22, 367

Index

- FCY23*, 367
Ferricrocin, 246
Fet3, 246
FK506, mucormycosis management, 489–490
FKS, substitutions and polymorphisms in drug resistance, 373–374
FKSI, 171–172, 373–374, 376, 420
FKS2, 373, 376, 420
Flo8, 203
Fluconazole
 candidiasis management, 338–341, 352
 combination therapy, 277–278
 Cryptococcus treatment, 342, 351
 endemic fungi infection management, 357
 mechanism of action, 273, 277
 pharmacodynamics, 310
 structure, 273
Flucytosine
 black fungus management, 530
 candidiasis management, 341, 351
 clinical implications, 309
 concentration effect, pharmacodynamic index, and target, 308–309
 Cryptococcus treatment, 342
 uptake, 367
5-Fluorocytosine. *See* Flucytosine
Folliculitis, *Malassezia* role, 477
Fonsecaea, 525–526
Fonsecaea monophora, 525
Fonsecaea pedrosoi, 525
Fonsecaea rubrica, 525
FsC, 246
Ftr1, 246
Fusarium, 14, 31
Fusarium oxysporum, 14
Fusarium solanum, 14
- ### G
- GAL1*, 241
Gal4, 241
GAL7, 241
GAL10, 241
Galactomannan, diagnostics, 265–266
Galactosaminogalactan, 224–225
GAP1, 239
Gap1, 197
GAP2, 239
Gastrointestinal tract, innate immunity, 124
Gat1, 247
Gat201, 66, 185
Gat204, 66, 185
GATA2, mutations and fungal infection susceptibility, 150
GCA1, 172
GCA2, 172
- GCN4*, 240
Gcn4, 244, 248
Gcr1, 241
Gcr2, 241
Genito-urinary tract, innate immunity, 124
Ggt1, 246
Gic1, 199
Gic2, 199
Glucan synthesis, therapeutic targeting, 274, 277–278, 280, 364, 488
Glucuronoxylomannan, diagnostics, 264
Glycosylphosphatidylinositol (GPI), therapeutic targeting, 278–279
Gpa2, 203
GPI. *See* Glycosylphosphatidylinositol
Gpr1, 203
GRACE, 70
GRP78, 228, 486–487
GWT1, 279–280
- ### H
- Hap3, 247
Hap5, 247
Haploinsufficiency profiling (HOP), 281
HapX, 246–247
Hda1, 204, 207
Heat intolerance, pathogenic fungi, 2
Hematopoietic stem cell transplantation (HSCT), invasive aspergillosis, 440
HER2, 221
Herpotrichiellaceae, 518–519, 523
Heterobasidion annosum, 26
High osmolarity glycerol response (HOG), 400–401
Histoplasma, 4–6, 24, 31
Histoplasma capsulatum
 amino acid metabolism, 240
 antibody therapy, 287
 B-cell immunity, 107–109
 dendritic cell response, 94, 96
 diagnosis, 259, 265–266
 evolution, 27, 31
 innate immunity, 130
 iron metabolism, 246
 macrophage engulfment, survival, and replication, 187–188
 morphogenesis, 201–202, 205
 overview, 4–7
 pattern recognition receptors, 100–101
 T-cell immunity, 102–107
 thermal dimorphism, 454–456
HIV/AIDS
 cryptococcal meningoencephalitis treatment, 339, 342
 Cryptococcus infection, 47, 185, 265, 285, 292, 342, 344, 350–352, 357, 388, 420
 mucormycosis, 485

- opportunistic infection trends, 272, 285, 351
 - oral mycobiome, 556–557
 - Paracoccidioides brasiliensis* infection, 456
 - Pneumocystis pneumonia*. *See Pneumocystis pneumonia*
 - transmission, 15
 - vaccination, 292
 - HOG. *See* High osmolarity glycerol response
 - Hog1, 182, 204, 402
 - Holleya sinECAUDA*, 201
 - HOP. *See* Haploinsufficiency profiling
 - HOP1*, 79
 - Hortaea*, 526
 - Hortaea werneckii*, 526
 - HSCT. *See* Hematopoietic stem cell transplantation
 - Hsp90, drug resistance
 - azoles, 372
 - echinocandins, 376
 - HWPI*, 165, 169, 202
 - Hydroxyferricrocin, 246
 - Hyphae. *See also* Morphogenesis
 - Aspergillus*, 13
 - biofilms, 166
 - Cryptococcus neoformans* reproduction in formation, 42–43
 - dimorphism. *See* Thermally dimorphic fungi
 - infection role, 2–3
 - melanization. *See* Black fungi
 - Hyr1, 164, 202
- I**
- IA. *See* Invasive aspergillosis
 - ICL1*, 241–243
 - ICP. *See* Intracranial pressure
 - Ifd6, 371
 - IFN- γ . *See* Interferon- γ
 - IL-2. *See* Interleukin-2
 - IL-12. *See* Interleukin-12
 - IL-17. *See* Interleukin-17
 - ILC. *See* Innate lymphoid cell
 - Immune reconstitution syndrome (IRS), 330, 344
 - Immunodiffusion, diagnostics, 259
 - Immunotherapy
 - antibody therapy, 286–289
 - dendritic cell immunotherapy, 289–290
 - Infection susceptibility
 - anhidrotic ectodermal dysplasia with immunodeficiency, 153
 - APECED, 150–151
 - chronic granulomatous disease, 141, 146
 - cytokine signaling disorders
 - interferon- γ , 147
 - interleukin-2, 148
 - interleukin-12, 147
 - interleukin-17, 147–148
 - Dectin-1–CARD9 signaling defects, 152–153
 - DOCK8 deficiency, 153
 - GATA2 mutations, 150
 - interferon regulatory factor 8 mutations, 151–152
 - myeloperoxidase deficiency, 146–147
 - overview of primary immunodeficiencies, 139–145
 - prospects for study, 154–155
 - STAT1 mutations, 149–150
 - STAT3 mutations, 148–149
 - STK4/MST1 mutation, 154
 - TYK2 deficiency, 153
 - Inflammasome, innate immunity, 129–130
 - Inflammatory bowel disease, mycobiome, 558–560
 - InIA, 221
 - Innate lymphoid cell (ILC), functional overview, 122–123
 - Interferon regulatory factor 8 (IRF8), mutations and fungal infection susceptibility, 151–152
 - Interferon- γ (IFN- γ), signaling defects and fungal infection susceptibility, 147
 - Interleukin-2 (IL-2), 148
 - Interleukin-12 (IL-12), signaling defects and fungal infection susceptibility, 147
 - Interleukin-17 (IL-17)
 - innate immunity, 128–129
 - signaling defects and fungal infection susceptibility, 147–148
 - Intracranial pressure (ICP), elevation management, 343
 - Invasive aspergillosis (IA)
 - antifungal clinical trials
 - overview, 354–355
 - prospects, 355
 - clinical presentation, 439–440
 - diagnosis, 440–441
 - drug development
 - overview, 354–355
 - prospects, 355
 - drug resistance. *See* Drug resistance
 - ecology, 433
 - epidemiology, 440
 - history of study, 431–432
 - laboratory identification and biology, 433–436
 - pathogenesis, 436–439
 - taxonomy and nomenclature of pathogens, 432–433
 - treatment, 441–442
 - IRF8. *See* Interferon regulatory factor 8
 - Iron
 - assimilation, 245–246
 - homeostasis regulation, 246–247
 - IRS. *See* Immune reconstitution syndrome
 - Itraconazole
 - adverse effects, 328
 - black fungus management, 530–531
 - candidiasis management, 338
 - endemic fungi infection management, 356–357
 - entomophthoromycosis management, 506

Index

K

Ketoconazole, endemic fungi infection management, 356–357
KI. *See* Potassium iodide
Knufia, 526
Knufia epidermidis, 526
KRE6, 280

L

Lacazia, 7
Lacazia loboi, 4
Las17, 199
LDF1, 188
Legionella pneumophila, 185
Leptosphaeria, 525
LFD6, 172
Lichtheimia
 genome studies, 493–494
 mucormycosis. *See* Mucormycosis
LOH. *See* Loss of heterozygosity
Loss of heterozygosity (LOH)
 aneuploidy, 84–86
 drug resistance role, 370
Lung transplantation, lung mycobiome, 558
LYPI, 188

M

MAC1, 399
Macrophage
 functional overview, 121–122, 179–180
 pathogen survival and replication
 Aspergillus fumigatus, 184–185
 Candida, 180–184
 Coccidioides, 186–187
 Cryptococcus, 185–186
 Histoplasma capsulatum, 187–188
Madurella, 526
Madurella grisea, 526
Madurella mycetomatis, 526
Malassezia
 evolution, 25
 genome features, 469
 innate immunity, 101, 127
 morphogenesis, 201
 mycobiome analysis of skin, 469–470
 overview, 474–475
 phylogenetic relationships, 468
 skin diseases
 atopic dermatitis, 475–476
 dandruff, 475
 folliculitis, 477
 overview, 467–469
 pathogenesis, 477–478
 pityriasis versicolor, 476–477

 psoriasis, 477
 seborrheic dermatitis, 475, 477
Malassezia globosa, 32
Malassezia sympodialis, 32
Manganese, transport, 247
Mannose receptor (MR), pathogen recognition, 101–102, 127–128
MAT, 75
MAT1-1, 51–52, 75
MAT1-2, 51–52, 75
MAT α , 388, 391
MCL, pathogen recognition, pathogen recognition, 101
MCM7, 435
MDH1, 242
MDR, expression in azole resistance
 cis-acting elements, 368
 overview, 368
 trans-acting elements, 368–370
Medicopsis, 526
Melanin
 Cryptococcus capsule melanization, 397
 pathogens. *See* Black fungi
Mendelian susceptibility to mycobacterial disease (MSMD), 147
MEP1, 238
MEP2, 238–239
Meristospore, 498
Metabolism. *See* Carbon assimilation; Iron; Nitrogen assimilation; Zinc
Mfa1, 48
Mfa1, 48
MFS transporters, 368
MIC. *See* Minimum inhibitory concentration
Micafungin, 340, 374
Microsporium, 8, 31
Mid1, 206
Mig1, 241
Mincle, pathogen recognition, 101, 127
Minimum inhibitory concentration (MIC)
 echinocandins, 311–312
 efficacy predictions, 304–306
 flucytosine, 309
 overview, 300–303
 polyenes, 307–308
 triazoles, 309–310
MK-3118, 279
Mkc1, 172, 376
MLS1, 242
Mls1, 243
Mod5, 198
Molecular phylogenetics, fungus evolution, 24–26
Monocyte
 functional overview, 121–122
 pathogen interactions, 97–98
Monophosphoryl lipid A (MPL), vaccine adjuvant, 293–294

- Morphogenesis
 community development, 207–209
 cytoskeleton, 198
 dimorphism. *See* Thermally dimorphic fungi
 evolution, 197
 fungal life cycle, 206–207
 hyphae
 contact sensing, 206
 nutritional and environmental signal sensing, 202–206
 overview, 195–196
 quorum sensing, 206
 transcriptional regulation, 206
 niche adaptation and fungal virulence, 200–202
 polarization, 193–195
 positional markers, 198–199
 prospects for study, 209
 signal transduction, 199–200
 vesicle trafficking, 197–198
 yeast
 Ascomycetes, 196
 Basidiomycetes, 196–197
- Mpk1, 400, 402
- MPL. *See* Monophosphoryl lipid A
- MPO. *See* Myeloperoxidase
- MR. *See* Mannose receptor
- MRR1*, 86, 369
- MSMD. *See* Mendelian susceptibility to mycobacterial disease
- MST1, mutation and fungal infection susceptibility, 154
- MPL*, 47, 49, 167, 419
- Mucorales, 14–15, 25, 227–229, 484–485, 490
- Mucor circillenioides*, 15, 493–494
- Mucormycosis
 genome studies
 Lichtheimia, 493–494
 miscellaneous genomes, 494
 Mucor circillenioides, 493
 Rhizopus, 490–493
 host–pathogen interactions, 486–487
 pathogens, 484–485
 susceptibility factors, 485–486
 treatment
 combination therapy, 488–489
 iron chelation therapy, 489–490
 monotherapy, 487–488
 overview, 487
- Mycobacterium tuberculosis*, 5, 101
- Mycobiome
 Candida vaginosis, 560
 Clostridium difficile diarrhea, 558–560
 development in humans, 555–556
 inflammatory bowel disease, 558–560
 lung mycobiome and lung transplantation, 558
 mapping, 554–555
 oral mycobiome and HIV, 556–558
 prospects, 560
 skin, 469–470, 554
- Mycosphaerella graminicola*, 33, 201
- MyD88, 125
- Myeloperoxidase (MPO), deficiency and fungal infection susceptibility, 146–147
- N**
- NADPH oxidase, defects and fungal infection susceptibility, 141, 146
- Natural killer (NK) cell
 functional overview, 122
 invariant cells, 122–123
- Nectria*, 14
- NEMO, 154
- Neosartorya fumigata*, 51
- Neosartorya udagawae*, 52, 146
- Neoscytalidium*, 526–527
- Neoscytalidium dimidiatum*, 526
- Neotestudina*, 24
- NET. *See* Neutrophil extracellular trap
- Neurospora*, 29, 31
- Neurospora crassa*, 26, 28, 34
- Neutrophil, functional overview, 121
- Neutrophil extracellular trap (NET), 121, 438
- NGT1*, 205
- NGT2*, 205
- Nitrogen assimilation
 host niches, 237–239
 overview, 236–237
 peptide and amino acid transporters, 237
 proteases, 237
 regulation, 239–240
- NK cell. *See* Natural killer cell
- NLRC4, 130
- NLRP3, 130
- Nod-like receptors, 129–130
- NRG1*, 203–204, 206
- nsdD, 52
- NSE, 198
- O**
- Ochoconis*, 527
- Ofd1, 204
- Onygenales, 4–8, 24
- Ophiocordyceps*, 24
- Ophiostoma*, 53
- Ophiostoma ulmi*, 201
- Oropharyngeal candidiasis, 129
- OXR1*, 188
- P**
- Paecilomyces lilacinus*, 146
- Paecilomyces variotii*, 146

Index

- PAFE. *See* Postantifungal effect
- Paracoccidioides*, 7, 10, 31
- Paracoccidioides brasiliensis*
- amino acid metabolism, 240
 - dendritic cell immunotherapy, 290
 - innate immunity, 121
 - morphogenesis, 201
 - overview, 4
 - T-cell immunity, 102
 - thermal dimorphism, 456–457
- Paracoccidioides lutzii*, 4
- Parnafungin A, 279
- Pattern recognition receptors. *See specific receptors*
- Pbs2, 204
- PBX1, 67
- PBX2, 67
- Pck1, 241
- Pcl103, 197
- PcMei2, 548
- PCP. *See Pneumocystis pneumonia*
- PCR. *See* Polymerase chain reaction
- PcRan1, 548
- PDR transporters, 367, 369–370
- PDR1, 420
- Penicillium*, 24, 30
- Penicillium marneffii*
- evolution, 27
 - morphogenesis, 201
 - overview, 5
 - thermal dimorphism, 458–460
- Pes1, 207
- PFK2, 242–243
- Phaeoacremonium*, 527
- Phaeoacremonium alvesii*, 527
- Phaeoacremonium amstelodamense*, 527
- Phaeoacremonium griseorubrum*, 527
- Phaeoacremonium inflatipes*, 527
- Phaeoacremonium krajdienii*, 527
- Phaeoacremonium parasiticum*, 527
- Phaeoacremonium rubrigenum*, 527
- Phaeoacremonium tardicrescens*, 527
- Phaeoacremonium venezuelense*, 527
- Pharmacodynamics, antifungals
- animal models, 301
 - combination therapy analysis, 312–313
 - echinocandins
 - clinical implications, 312
 - concentration effect, pharmacodynamic index, and target, 311–312 - experimental measures and predictions, 301–307
 - flucytosine
 - clinical implications, 309
 - concentration effect, pharmacodynamic index, and target, 308–309 - in vitro studies, 300–301
 - polyenes
 - amphotericin B lipid formulations, 307–308
 - clinical implications, 308
 - concentration effect, pharmacodynamic index, and target, 307
- triazoles
- clinical implications, 310–311
 - concentration effect, pharmacodynamic index, and target, 309–310
- Pharmacokinetics, antifungals
- animal models, 301
 - combination therapy analysis, 312–313
 - epithelial lining fluid measurements, 299–300
 - experimental measures and predictions, 301–307
 - in vitro studies, 300–301
 - overview, 299–300
- Phialophora*, 527
- Phialophora europaea*, 527
- Phoma*, 527–528
- Phospholamban (PLB), 186
- Phospholipase B, 398
- Phospholipase D (PLD), 225
- Phosphoraceae*, 519
- Phosphoraceae europaea*, 520
- Phr1, 172
- Pityriasis versicolor (PV), *Malassezia* role, 476–477
- PKA. *See* Protein kinase A
- PKC. *See* Protein kinase C
- PLB. *See* Phospholamban
- PLB1*, 398
- PLD. *See* Phospholipase D
- Ploidy change. *See also* Aneuploidy
- overview, 73–75
 - sexual reproduction mediation
 - endoreduplication and mitotic collapse, 79–80
 - meiosis versus parasex, 78–79
 - overview, 75–76
 - parasexual reproduction mediation, 76–78
- Pneumocystis*
- epidemiology, 540
 - evolution, 24
 - history of study, 539
 - innate immunity, 104
 - life cycle, 540–541
 - morphology, 541–542
 - systematic position within Fungi, 540
 - unique features, 546–547
 - virulence factors and drug targets, 547–548
- Pneumocystis carinii*
- biofilm, 162
 - innate immunity, 126–127
 - life cycle, 541
 - morphology, 542
- Pneumocystis jirovecii*
- cell invasion, 228–229
 - morphology, 542
 - overview, 7, 14, 540–542

- Pneumocystis murina*
biofilm, 162
innate immunity, 122
life cycle, 541
morphology, 542
- Pneumocystis pneumonia* (PCP)
animal models, 544–545
diagnosis, 543
epidemiology, 540
pathogenesis, 543–546
treatment, 543
- Polarity. *See* Morphogenesis
- Polymerase chain reaction (PCR), diagnostics,
259–262, 264
- Population genetics
Cryptococcus neoformans reproduction studies,
45–47
fungus evolution, 26–30
- Population genomics, fungus evolution, 32–35
- Posaconazole
candidiasis management, 338
indications, 274
pharmacokinetics and pharmacodynamics,
327–328
structure, 273
- Postantifungal effect (PAFE), 302, 307, 309
- Potassium iodide (KI), entomophthoramycesis
management, 506–507
- PRA1*, 247
- PRB1*, 239
- PRB2*, 239
- PRC1*, 239
- Protein kinase A (PKA)
high osmolarity glycerol response,
400–401
morphogenesis role, 203–205
- Protein kinase C (PKC)
biofilm formation role, 172–173
high osmolarity glycerol response, 400–401
- Proteomics, diagnostics, 262–263
- Pseudallescheria*, 24
- Pseudoallescheria boydii*, 14
- Pseudochaetosphaerionema*, 528
- Pseudochaetosphaerionema larense*, 528
- Pseudomonas aeruginosa*, biofilm, 166, 168
- Psoriasis, *Malassezia* role, 477
- Ptp2, 204
- Ptp3, 204
- PV. *See* Pityriasis versicolor
- PYK1*, 242–243
- Pyrenochaeta*, 528
- Pyrenochaeta keratinophila*, 528
- Pyrenochaeta mackinnonii*, 528
- Pyrenochaeta romeroi*, 528
- Pyrenochaeta unguis-hominis*, 528
- Pythium insidiosum*, 25
- Q**
Quorum sensing, hyphal morphogenesis, 206
- R**
RAC1, 199–200
RAC2, 199–200
Ramichloridium, 14
Ras1, 199, 203, 206–208
Ras2, 203
Rax1, 198
Rax2, 198
Reproduction, sexual
Aspergillus fumigatus
drug resistance role, 53
other *Aspergillus* species, 521
overview, 51
pathogen population biology significance, 52–53
sexual cycle, 51–52
Candida albicans parasexual reproduction, 47–51
Cryptococcus neoformans a- α opposite sex bisexual
reproduction
genetic hybrid studies, 44
monokaryotic fruiting, 43
overview, 42
population genetics studies, 45–47
unisexual reproduction, 43–44
virulence links, 47
overview, 41–42
ploidy change mediation
endoreduplication and mitotic collapse, 79–80
meiosis versus parasex, 78–79
overview, 75–76
parasexual reproduction mediation, 76–78
prospects for study, 53–54
Respiratory tract, innate immunity, 124
RHAMM, 227
Rhinocladiella, 528
Rhinocladiella aquaspersa, 528
Rhinocladiella basitona, 528
Rhinocladiella similis, 528
Rhinosporidium, 25
Rhizopus, 15, 25. *See also* Mucormycosis
Rhizopus delemar, 492–493
Rhizopus microsporus, 491, 493
Rhizopus oryzae, 15, 485–486, 488, 492–493
Rhizopus stolonifer, 491
Rho1, 195, 199
Rho101, 197
Rho104, 197
Ribosomal DNA
diagnostics, 261
molecular phylogenetics, 24
Rim20, 205
Rim21, 205
Rim101, 197, 247

Index

RLM1, 172
Rlm1, 374
RodA, 224
RPB1, 435
RPB2, 435
RPM1, 170
Rtt109, 548

S

Saccharomyces cerevisiae, 10
 carbon assimilation, 241–242
 cross-species genetic interaction mapping, 67
 dendritic cell response, 96
 evolution, 26–29, 33
 genome profiling
 functional annotation, 63–64
 libraries, 62–63
 systematic approach, 63
 morphogenesis, 197–199, 452
 ploidy change, 73–75, 79, 82–82
 reproduction, 47
Saccharomyces paradoxus, 33
Sap2, 237, 293
Scedosporium anamorphs, 14
SCH B, 278–279
Schizophyllum commune, 26
Schizosaccharomyces pombe
 morphogenesis, 197–198
 ploidy change, 73–75
SCID. *See* Severe combined immunodeficiency
Scp1, 400
SD. *See* Seborrhic dermatitis
Seborrhic dermatitis (SD), *Malassezia* role, 475, 477
SEC6, 399
Sef1, 246
SET3, 419
Severe combined immunodeficiency (SCID), 148
Sexual reproduction. *See* Reproduction, sexual
SFL1, 183
SFL2, 419
Sfu1, 246
SID1, 188
SID3, 188
SID4, 188
Sit1, 246, 399
Skin
 diseases. *See specific diseases and pathogens*
 innate immunity, 123–124
Slt2, 376
SMI1, 172
Smil, 374
Snf5, 69
SNQ2, 367
SOD1, 186
Sod1, 183

Sod4, 183
SOK1, 206
SOU1, 83
SOWgp, 187, 454
SPA, 438
Spa2, 207
SPD, 438
Sporothrix, 24
Sporothrix schenckii
 overview, 5
 cell invasion, 229
 thermal dimorphism, 457–458
SrcA, 246
SRE1, 400
SreA, 247
SREBP, pathway in *Cryptococcus neoformans* virulence,
 66–67
Ssa1, 221–222
Ssk2, 204
Ssy5, 239
Staphylococcus aureus, 168, 260
STAT1, mutations and fungal infection susceptibility,
 149–150
STAT3, 129, 148–149
STK4, mutation and fungal infection susceptibility, 154
Stp1, 239
Stp2, 238–239
Surfactant protein D, 229
Susceptibility. *See* Infection susceptibility

T

TAC1, 77, 85–86, 368, 370–371
TAFc, 246
Talaromyces marneffii. *See Penicillium marneffii*
Tapesia yallundae, 53
T cell
 CD8 T cells, 107
 regulatory T cells, 106–107
 Th1 immunity, 102–103
 Th2 immunity, 103–104
 Th17 immunity, 104–106
Tea1, 198
Terbinafine, black fungus management, 530
TGF- β . *See* Transforming growth factor- β
Thermally dimorphic fungi
 overview, 449–450, 452
 origins, 449–451
 phylogenetic analysis of pathogens, 451
 Blastomyces dermatitides, 452–453
 Coccidioides immitis, 453–454
 Coccidioides posadasii, 453–454
 Histoplasma capsulatum, 454–456
 Paracoccidioides brasiliensis, 456–457
 Sporothrix schenckii, 457–458
 Penicillium marneffii, 458–460

TLR. *See* Toll-like receptor
TNF- α . *See* Tumor necrosis factor- α
Toll-like receptor (TLR), overview, 98–99, 125–126
TPK1, 168
Tpk1, 203
Tpk2, 203
Transforming growth factor- β (TGF- β), cell invasion enhancement, 228–229
Treatment principles, mold infection
 acute versus chronic treatment, 330
 adverse effects of antifungal drugs, 328–329
 Candida. *See* *Candida* treatment principles
 Cryptococcus. *See* *Cryptococcus* treatment principles
 early diagnosis, 329
 epidemiology in local area, 329
 evidence-based treatment guidelines, 331–332
 immunosuppression level of patient, 330
 multidisciplinary approach, 330–331
 overview, 323–324
 pathogenesis and natural history of infection, 325–326
 pharmacokinetics and pharmacodynamics, 326–328
 spectrum of activity of antifungal drugs, 324
Trematosphaeria, 528–529
Trematosphaeria grisea, 528
Trichophyton, 8, 24, 31, 124
Trichophyton rubrum, 29, 202
Trichosporon, 25
Trimethoprim-sulfamethoxazole, *Pneumocystis* pneumonia management, 543
TSR1, 435
Tumor necrosis factor- α (TNF- α), fungus immune response, 102
Tup1, 244, 247
TYK2, deficiency and fungal infection susceptibility, 153

U

ubi4, 239
Ubr1, 206
Umbelopsis ramanniana, 494
UME6, 419–420
Ume6, 204, 207
Uncinocarpus reesii, 31
UPC2, 85
URA3, 68
URE1, 186, 398–399
Ure1, 226
Urease, 238, 398–399, 454
Ustilago maydis, 201, 207

V

Vaccination
 attenuated vaccines, 291–292
 conjugate vaccines, 293–294
 dendritic cell vaccination, 290
 killed vaccines, 291–292
 overview, 291
 recombinant protein vaccines, 292–293
Valley fever, 186
Veronaea, 529
Veronaea botrysa, 529
Verruconis, 529
Verticillium, 201
Virulence factors, criteria for pathogenicity, 2–3
Vomocytosis, 186
Voriconazole
 adverse effects, 328–329
 black fungus management, 531
 candidiasis management, 338–340
 invasive aspergillosis management, 355–356, 442
 mechanism of action, 273–274
 mucormycosis management, 488
 pharmacokinetics and pharmacodynamics, 327
 structure, 273
Vulvovaginal candidiasis (VVC), 125, 560
VVC. *See* Vulvovaginal candidiasis

X

Xog1, 172

Y

YAP1, 183
Yap1, 207, 438
YHB1, 183
Yps3, 6, 202, 455

Z

ZAP1, 399
Zap1, 172, 371
ZCF39, 419
Zinc, assimilation, 247–248
Znf2, 209
ZO-1, 226
ZrfC, 247
Zrt1, 247
Zygosporium, 498